• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Lovenox (enoxaparin sodium) Injection

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Lovenox (enoxaparin sodium) Injection

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Lovenox (enoxaparin sodium) Injection has been approved for use in the prevention of deep vein thrombosis (DVT) which may lead to pulmonary embolism (blood clots in the lung) in patients undergoing abdominal surgery who are at risk for thromboembolic complications.

    Surgical patients at risk include those who are over 40 years of age, obese, undergoing surgery with general anesthesia longer than 30 minutes, or who have additional risk factors such as a malignant tumor or a history of deep vein thrombosis or pulmonary embolism.

    A new indication for Lovenox was approved in March of 1998. This indication is for the prevention of ischemic complications of unstable angina and non-Q-wave myocardial infarction (heart attack) when concurrently administered with aspirin. Unstable angina is a serious condition that can lead to heart attack or death.

    Additional Information

    Deep vein thrombosis is the formation of blood clots which may lead to pulmonary embolism. Pulmonary embolism occurs when a clot circulates and lodges in the lungs, and can cause sudden death. Venous thromboembolic disease is responsible for more than 400,000 hospitalizations and up to 200,000 deaths each year in the U.S.

    Approval Date: 1997-05-01
    Company Name: Rhone Poulenc Rorer
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Virtual Doctoer

      Simple Changes Can Make Trials More Patient Friendly

    • Drug approval

      Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

    • VaccinewithNeedle-360x240.png

      Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

    • AskTheExperts-360x240.png

      Ask the Experts: Trial Operations Adjustments in a Remote World

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing